Ocugen Eases on Tests

Ocugen, Inc. (OCGN) shares fell slightly as the company announced the first patient was dosed in its global Phase 3 trial for OCU410, a gene therapy for dry age-related macular degeneration. The FDA granted RMAT designation to OCU410, potentially accelerating development. The trial follows a successful End-of-Phase 2 meeting with the FDA.

Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ocugen Provides Business Update with Second Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET · Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry ag

Ocugen (NASDAQ: OCGN) said it signed a binding term sheet to negotiate an exclusive license for its OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa with Roots Pharmaceutical and Al-Dhow International Holding. Ocugen expects up to $4 million in upfront and near-term milestones, up to $255 million in sales milestones, and 22% royalties on net sales. Ocugen will manufacture OCU400, with a definitive deal expected within 90 days.

AMD unveiled two AI-focused hardware platforms at IFA 2026: the Ryzen AI Max Pro 400 (Kraken Halo) and the Threadripper Halo Station. The former, with unified memory, can run 300-billion-parameter AI models locally. The latter, a liquid-cooled workstation, supports over 1-trillion-parameter models. AMD claims local AI reduces costs versus cloud-based solutions, citing industry data on token usage and pricing.

SoFi Technologies and Kraken's parent company, Payward, have partnered to connect their products. Kraken's institutional clients will use SoFi's dollar settlement network, and SoFi will use Kraken Prime for digital asset liquidity. SoFi's stablecoin, SoFiUSD, will be added to Kraken's platforms. According to experts, this partnership reflects the growing integration of digital assets into traditional banking.

Studsvik AB, a Swedish nuclear services company, agreed with GE Vernova Hitachi (GVH) and Samsung C&T to build 1.2 GW of nuclear energy using the BWRX-300 reactor design. The project, targeting operation in the mid-2030s, will be developed at one of two sites. Studsvik, with a market cap under $200M and 2025 revenue under $100M, acquired Kärnfull Next earlier this year, entering reactor development. This follows GE Vernova's loss to Rolls-Royce in a prior Swedish nuclear project.